Commercializing Rare-Disease Therapies Is Getting Tougher
Until the Evidence is There: A Conversation with Michael Sherman, Point32Health
Dodging the Sword: The Cost-Saving Opportunity in Biologicals
A Solution to the Medicare Copay Problem
Insights from PCMA: top market access signals
Paying for Gene/Cell Therapies is Only Half the Problem
On rare drugs, is ICER at least partly right?
The Medicare copay problem ain’t going away. Here’s how we can do better by patients.
It’s Time to Put Innovative Contracts Under Warranty
Survey Results: What (if any) drug pricing reform is likely to come in the next few years?